Physicians Realty Trust Stock News

If you want $10,000 per month, or $120k a year, this is a tall order unless you have a huge portfolio.

Three years of persistent rate-driven pressure on the residential and commercial real estate market appears to finally be abating - and not a moment too soon. REITs were hit by a "triple whammy" of rate-related headwinds: higher borrowing costs directly squeezed profitability, eroded the relative appeal of REIT dividends, and made it near-impossible to grow accretively. Since the Fed's initial ...

Sixteen of the thirty-eight highest-yield, 'safer' S&P 500 dividend stocks are highlighted as ready to buy, with adequate free cash flow supporting payouts. Analyst forecasts suggest top ten S&P 500 dividend 'dogs' could deliver 20.45% to 38.5% net gains by September 2026, with an average gain of 27.35%. Stocks like Amcor, Healthpeak, Conagra, Pfizer, and Verizon offer the best combination of h...

Finding undervalued stocks isn't easy these days. The average stock price for companies in the benchmark S&P 500 index has soared to 24.8 times trailing 12-month earnings.

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (Sept. 2025)

DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (“Healthpeak”) (NYSE: DOC) announced today the release of its 14th annual 2024 Corporate Impact Report (the “Report”). The Report highlights Healthpeak's continued focus on building a resilient portfolio, advancing sustainability goals, fostering a workplace culture guided by its WE CARE core values, and promoting sound corporate governance a...

Market volatility favors value stocks like Healthpeak Properties, which offers downside protection, a near-7% yield, and trades at a bargain valuation. DOC's recent results showed strong same-store NOI growth in outpatient medical and senior housing, with robust leasing and high tenant retention rates. DOC carries a BBB+ credit rating, a well-covered 6.8% dividend yield, and ample liquidity, su...

Healthpeak Properties offers a compelling near-7% yield, low valuation, and long-term upside despite recent post-earnings sell-off and sector headwinds. Q2 results showed flat FFO but solid AFFO growth, strong same-store performance outside the lab segment, and reaffirmed full-year guidance covering the dividend. The balance sheet remains robust with manageable leverage, strong liquidity, and w...